Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    ANGIOMA, HEREDITARY NEUROCUTANEOUS
Show Display Options
Rank Status Study
1 Completed
Has Results
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Conditions: CNS Cancer;   Meningioma;   Intracranial Hemangiopericytoma;   Hemangioblastoma;   Neurofibromatosis
Intervention: Drug: Sunitinib
2 Active, not recruiting Stereotactic Body Radiotherapy for Spine Tumors
Conditions: Spinal Metastases;   Vertebral Metastases;   Benign Spinal Tumors;   Chordoma;   Meningioma;   Schwannoma;   Neurofibroma;   Paragangliomas;   Arteriovenous Malformations
Intervention: Radiation: stereotactic body radiotherapy

Indicates status has not been verified in more than two years